基本分析
透過季節調整季營收，判斷美股整體趨勢，但注意股價有時候領先基本面的數據，應搭配其他領先指標判斷。
基本資料
個股的基本資料，以及所屬的類股和產業。
公司介紹
業務介紹
艾克薩斯科學公司在美國和國際上提供癌症篩查和診斷測試產品。該公司提供Cologuard,這是一種非侵入性的糞便DNA篩查測試,用於檢測與結腸直腸癌和癌前病變相關的DNA和血紅蛋白生物標誌物。它還提供Oncotype DX,這是一種用於乳腺癌、前列腺癌和結腸癌的基因表達測試;Oncotype Test,這是一種組織測試,可提供腫瘤分析,以幫助選擇治療方案,適用於晚期、轉移性、難治性或復發性癌症患者;Oncotype DX AR-V7 Nucleus Detect Test,這是一種用於晚期前列腺癌的液體檢測;Oncomap ExTra,提供某些難治性、罕見或侵略性癌症的完整生物學圖像;以及Covid-19檢測服務。該公司的管線產品專注於提高Cologuard測試的性能特徵,並開發基於血液和其他體液的測試。它與梅奧基金會for Medical Education and Research以及Hologic, Inc.有許可協議。艾克薩斯科學公司成立於1995年,總部位於威斯康星州麥迪遜。
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
警語
1. 資料僅供參考，不做任何獲利保證及特定股票與點位推薦建議。
2. 資料並不完整，需要完整資料請至相關網站索取。
3. 任何股市數據分析皆存在倖存者偏差。
